- $53.65m
- -$46.08m
- $9.85m
Brief: Kronos Bio Q1 EPS USD -0.5
Kronos Bio Inc expected to post a loss of 42 cents a share - Earnings Preview
Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Kronos Bio Q4 EPS USD -0.43
Kronos Bio Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Kronos Bio Inc - In Connection With Reduction In Workforce, Company Expects To Incur Charges Of About $0.5 Million Primarily In Q1
Brief: Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
U.S. RESEARCH ROUNDUP-Array Technologies, Autodesk, Nike
Brief: Kronos Bio Announces Pipeline Update And P300 Kat Inhibitor Development Candidate
Kronos Bio falls as co will not proceed with mid-stage trial for cancer therapy
Brief: Norbert Bischofberger Reports 17.4% Stake In Kronos Bio, Inc.
Brief: Kronos Bio Q3 Net Income USD -31.374 Million
Kronos Bio Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Kronos Bio Presents Positive Preliminary Data From Phase 1 Dose Escalation Portion Of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC
Brief: Kronos Bio Announces Departure Of CFO And Head Of Corporate Development
Kronos Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Kronos Bio Q2 Net Income USD -29.741 Million
Kronos Bio Inc expected to post a loss of 46 cents a share - Earnings Preview
Kronos Bio Inc reports results for the quarter ended in March - Earnings Summary